Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
Article excerpt
Highlighted: the sentence this signal was extracted from
PLAINSBORO, N.J. and BAGSVÃRD, Denmark, Nov. 16, 2026 /PRNewswire/ -- Today, Novo Nordisk shared primary results from the phase 3 STEP Young trial evaluating the safety and efficacy of investigational once-weekly semaglutide injection, with a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight, in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity. 1 The results were presented during a scientific symposium at ObesityWeek ® 2026 and simultaneously published in The New England Journal of Medicine. 1,3 "Severe obesity can profoundly affect a child's physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood," said Ania M. Jastreboff, MD, PhD, Professor of Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology) at Yale School of Medicine and Director of the Yale Obesity Research Center (Y-Weight). "Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight related health." In the STEP Young trial, more than 85% of the children had class II or III severe obesity at...
Keep reading with a free account
The rest of this article, and every signal for Novo Nordisk, is in your free account.
